Videos

“I think [it was a] great opportunity to catch up on what is going on with PSMA-PET and theranostics and then also understand that that landscape will change over the near future,” says Kelly L. Stratton, MD, FACS.

“It really was a multidisciplinary effort to pull the data together [and] provide the clinical implications [of] the genetic markers,” says Veda N. Giri, MD.

“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.

“Clinicians should do whatever they're able to try to limit or reduce the need for an intraoperative transfusion,” says Timothy D. Lyon, MD, FACS.

“The bulk of what we’re all grappling with are these new data for combining PARP inhibitors with androgen receptor–targeted agents in molecularly unselected populations,” says Tanya Dorff, MD.

“Major bladder reconstructive surgeries have the most room for improvement, particularly surgeries involving a bowel anastomosis,” says Sarah Hecht, MD.

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

“We need to be focusing our efforts on early exposure to the field for women and underrepresented groups,” says Bridget Lang Findlay, MD.

“It's important to put out information that's both accurate and helps to supplement in-office decision making in an outpatient setting,” says Daniel Bockelman.

Laura Bukavina, MD, MPH, discusses a highlight from the 2022 Society of Urologic Oncology Annual Meeting.

“We've got a lot of movement in terms of understanding how stones form, some pharmaceutical interventions that we can use to prevent stones, and then how we can get even less invasive to try to get stones in the least morbid way for our patients,” says Thomas Chi, MD.

Dr Gershman summarizes recent imaging advances and remaining unmet needs for patients with prostate cancer, and envisions how the use of artificial intelligence may impact the field in the future.

A practical approach to how urologists might best communicate with radiologists and other clinicians regarding mpMRI results for patients with prostate cancer, with an emphasis on optimizing patient care.

“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.

Laura Bukavina, MD, MPH, summarizes a presentation from the 2022 Society of Urologic Oncology Annual Meeting from Sarah P. Psutka, MD, MS.

Dr Andriole shares remaining unmet needs in prostate cancer risk assessment and shares his hopes for the future.

An expert urologist summarizes the available CV and CU data for the various pre-biopsy biomarker test options, and opines on how use of these tests might impact patient risk stratification, subsequent management, and/or health outcomes.

“It’s important for us to get the tools necessary to deal with patients who come with a unique set of difficulties,” says Laura Bukavina, MD, MPH.

“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

"We're trying to figure out how to improve people's relationships with their genitals and like their sexual practices," says Christi Butler, MD.

Dr Chamie shares advice for community urologists treating patients with MIBC.

Karim Chamie, MD, explains how he might approach immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant settings in the future.

Dr Chamie comments on the significant unmet needs and clinical challenges in the management of MIBC.

Karim Chamie, MD, presents the case of a 77-year-old patient with T2N0M0 MIBC and the potential treatment regimen he would suggest.

Dr Chamie describes how he coordinates with medical oncologists after a referral for MIBC, and his strategies for following up with patients.

Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.

Dr Chamie explains how cisplatin eligibility is defined in patients with MIBC and how many patients in his practice receive neoadjuvant cisplatin therapy.

Karim Chamie, MD, presents the case of a 60-year-old patient with stage 3A muscle-invasive bladder cancer (MIBC) and explains her risk of disease recurrence and whether the case is similar to the patients he typically sees in his clinical practice.

“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.

An overview of the steps involved in the clinical application of mpMRI imaging, from image generation to results interpretation and follow-up.